David Zhen, MD

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of nivolumab plus ipilimumab and look back on last year's ODAC meeting on its use in PD-L1–negative gastrointestinal cancers.

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

David Zhen, MD, provides advice to oncologists treating patients with upper gastric cancer and offers closing thoughts on the future treatment landscape, highlighting challenges and unmet needs.

Turning the focus to ongoing research, an expert on upper gastric cancer discusses novel targets being investigated in clinical trials and the evolving treatment landscape.

A medical oncologist discusses the treatment of patients with gastric adenocarcinoma who have progressed following treatment with immunotherapy.

David Zhen, MD, provides clinical insights on the management of adverse events stemming from immunotherapy in patients with upper gastric cancer.

Expert perspectives on the role of immunotherapies in upper gastrointestinal cancers, highlighting the CheckMate 649 study investigating frontline nivolumab plus chemotherapy.

A medical oncologist reviews the available frontline treatment options for patients with gastric adenocarcinoma.

David Zhen, MD, reviews the profile of a 60-year-old man with stage IV gastric adenocarcinoma and offers his initial impressions on the case.